CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,101 enrolled
Drug / intervention
CP 690,550 5 mg +3 moredrug
Likely dose
CP 690,550 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01241591
NCT01241591Phase 3Completed
CompareCT.gov

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Pfizer·interventional·Posted Nov 16, 2010·Updated Dec 26, 2018

In Brief

A Phase 3 clinical trial evaluating CP 690,550 5 mg, CP 690,550 10 mg, and 2 other interventions for Psoriasis. Completed, enrolled 1,101 participants across 122 sites in 26 countries.

Detailed Summary

To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesArgentina, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Netherlands, Poland, Russia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 16, 2010
Enrollment StartNov 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.6 years ago

Interventions

CP 690,550 5 mgdrug

CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

CP 690,550 10 mgdrug

CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks

Etanercept 50 mgbiological

Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks

Placeboother

Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.